Methods for treatment of oncological disorders using an epimetabolic shifter (Coenzyme Q10)

Patent metadata

Field	Value
Publication number	US-10351915-B2
Application number	US-201815862856-A
Country	US
Kind code	B2
Filing date	Jan 5, 2018
Priority date	May 11, 2009
Publication date	Jul 16, 2019
Grant date	Jul 16, 2019

Abstract

Methods and formulations for treating onocological disorders in humans using Coenzyme Q10 are described.

First claim

The invention claimed is:

1. A method for treating pancreatic cancer in a human, comprising: intravenously administering Coenzyme Q10 (CoQ10) to the human at a dose of at least 5 mg/kg such that treatment occurs, wherein the CoQ10 is in its oxidized form and has a purity between 95% and 100%, and wherein administration of the CoQ10 to the human results in an increase of CoQ10 in the oxidized form in the human.

2. The method of claim 1 , wherein the treatment occurs via an interaction of Coenzyme Q10 with a protein selected from the group consisting of HNF4-alpha, Bcl-xl, Bcl-xS, BNIP-2, Bcl-2, Birc6, Bcl-2-L11 (Bim), XIAP, BRAF, Bax, c-Jun, Bmf, PUMA, cMyc, transaldolase 1, COQ1, COQ3, COQ6, prenyltransferase, 4-hydrobenzoate, neutrophil cytosolic factor 2, nitric oxide synthase 2A, superoxide dismutase 2, VDAC, Bax channel, ANT, Cytochrome c, complex 1, complex II, complex III, complex IV, Foxo 3a, DJ-1, IDH-1, Cpt1C, and Cam Kinase II and any one or more of genes listed in Tables 2-4 & 6-28.

3. The method of claim 1 , further comprising a treatment regimen selected from the group consisting of surgery, radiation, hormone therapy, antibody therapy, therapy with growth factors, cytokines, and chemotherapy.

4. The method of claim 1 , wherein the Coenzyme Q10 is administered with an additional therapeutic agent.

5. The method of claim 4 , wherein the Coenzyme Q10 is administered concurrently with the additional therapeutic agent.

6. The method of claim 4 , wherein the Coenzyme Q10 is administered prior to administration of the additional therapeutic agent.

7. The method of claim 4 , wherein the Coenzyme Q10 is administered subsequent to administration of the additional therapeutic agent.

8. The method of claim 4 , wherein the additional therapeutic agent is a chemotherapeutic agent.

9. The method of claim 8 , wherein the chemotherapeutic agent is gemcitabine.

Assignees

• Berg Llc

Inventors

• Narain Niven Rajin
• Mccook John Patrick

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title